
21 Jan Verve Therapeutics
Jason Politi, Chief Technical Operations Officer
Boston, Massachusetts
(NASDAQ: VERV)
At Verve, we are striving to build the preeminent company developing gene editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). We are leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of this condition that touches so many individuals worldwide, whether personally or through a loved one. Our goal is to disrupt the chronic care model for treating ASCVD by providing a new therapeutic approach with single-course gene editing medicines.